Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2022

View Archived Issues

Blocking UBE2N evades oncogenic immune signaling in AML

TYK2 inhibitors described by Ennovabio (Zhejiang) Pharmaceuticals, Shanghai Ennova Biopharmaceutical

New Bruton tyrosine kinase inhibitors identified at Beijing Innocare Medical Technology

Chengdu Fanxi Biopharma discovers thyroid hormone receptor alpha/beta agonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent Nav1.8 channel blockers

Medshine Discovery identifies new cyclin/CDK inhibitors

RIG1 activation confers protection against SARS-CoV-2 infection in mice

Study reveals dopamine as a sleep disorders target

Targeting PTP1B enhances T cell-mediated antitumor immunity

FDA grants orphan drug designation to HT-KIT for mastocytosis

Discovery of novel MDM2 inhibitor with antitumor activity in p53 wild-type cancer models

Del-1 potentiates BCI efficacy by blockade of tumor-infiltrating neutrophils

Bright Minds' BMB-101 for Dravet syndrome completes 28-day repeat toxicity studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...